Improving survival for patients with metastatic non-small cell lung cancer in the immunotherapy era

The article by Wang et al. demonstrates that immune checkpoint inhibitor therapy has increased survival for patients with metastatic non–small cell lung cancer, although the increases in overall survival and progression‐free survival are typically less than demonstrated in randomized controlled trials. These discrepancies are likely caused by lower rates of immune checkpoint inhibitor therapy in the real world compared to clinical trial populations and by differences in patient characteristics.